Eximore is developing ophthalmic drug delivery products. The company’s initial target development is a non-invasive punctal plug designed to release glaucoma drugs, controlled over a long period of time. Currently compliance is only about 30% with the eye drops containing the drugs, and as such glaucoma remains the leading cause of blindness. Eximore’s product will relieve the patients from the need to apply daily eye drops and will solve the compliance problem.
CEO- Ishay Attar